The US Treasury has proposed rules under the COINS Act that would bring biotechnology into the scope of outbound investment restrictions aimed at sensitive investments involving China. Beijing has responded by urging Washington to halt the expansion. The proposal also carves out licensing arrangements through which large pharmaceutical firms develop medicines in China, leaving those transactions outside the restriction.

The rule therefore contains two logics at once. One targets equity stakes and joint ventures, the channels through which research capability might be transferred to a competitor. The other leaves licensing arrangements alone, on the reasoning that blocking them outright would hit the in-China revenue of global drugmakers directly.

What Happened

• Legal basis: The proposal was issued under the COINS Act and opened for public comment, a formal disclosure step ahead of rulemaking.
• New scope: Biotechnology joins a framework that had previously concentrated on semiconductors, quantum information, and artificial intelligence.
• The carve-out: Licensing deals for large pharmaceutical firms were excluded, which biotech trade press read as a practical compromise with the commercial model of multinational pharma.
• Beijing’s response: Chinese officials urged the US to stop widening the scope, arguing that further expansion does not resolve problems.
• Industry concern: Several industry bodies noted that the treatment of new-entity structures and co-development agreements remains undefined, leaving substantial operational uncertainty.

Competing Views

Those favoring tighter rules argue biotechnology is structurally similar to the computing power already restricted. Advanced compute supplies raw processing capability, and certain segments of pharmaceutical research depend on comparable hard-to-replace platforms, data assets, and laboratory infrastructure. If those are left unregulated, restrictions on computing power can be partly offset through a different channel. Keeping the framework internally consistent, on this view, means extending it.

Those opposing expansion point out that the costs fall on more than competitors. Pharmaceutical development is deeply global, with a single approval typically depending on clinical data and manufacturing collaboration across several regions. Restricting capital flows raises development costs for the entire industry, and those costs ultimately reach patients through pricing and access. One cross-sector think tank noted that the presence of a carve-out shows policymakers understand exactly where the boundary lies.

From outside observers, trade press has focused on the difficulty of defining technology transfer. Equity structure, board seats, and the drafting of joint research agreements can all be adjusted to sit outside the formal limits, so the rule’s real bite depends on enforcement standards rather than text. That gives compliance teams months of restructuring work while narrowing the fundraising window for early-stage companies.

Panoramic Analysis

What makes this expansion worth noting is the nature of the asset now being restricted. Earlier rounds of US outbound investment tightening aimed largely at physical and substitutable equipment and compute, where alternatives existed at a higher price. Biotechnology points at knowledge assets instead: accumulated clinical data, laboratory workflows, and research organizations. Substituting those is far harder than substituting a machine tool.

That difference produces different consequences. Equipment restrictions raise costs. Capability restrictions narrow access: a company can buy a more expensive machine, but it cannot quickly buy an alternative research system. Once the target shifts from cost items to capability items, corporate response moves from supply-chain restructuring to organizational restructuring, which takes longer and is harder to unwind.

The carve-out is equally informative. It shows the rule’s authors did reach a judgment about where the boundary sits, and then chose to preserve it. That preservation protects US pharmaceutical industry interests and pharmaceutical supply security, neither of which aligns perfectly with the stated goal of outbound restrictions. Expect the definition of the carve-out to remain contested, and to be the main battleground in the quarters of rule refinement ahead.

Two longer-term watch points follow. First, enforcement standards: once the rule is final, the determination of what counts as a restricted investment becomes the real contest, and the space between formal compliance and substantive circumvention will stay wide. Second, spillover: capital-flow rules set by one major economy gradually become reference points for others, whether or not they are adopted, which means global biopharma capital allocation is being repriced by policy objectives in any case. For the industry, financing and licensing decisions after 2026 increasingly sit at the intersection of efficiency and political acceptability.

On Beijing’s response, the notable shift is that the argument moved from whether to tighten to whether to keep widening. The first confirms an accomplished fact; the second contests the remaining policy space. That difference in framing suggests the real contest will increasingly happen before rules are written.

Editor: GoodInfo Global News Team